Health Care Activity – Page 3

Cigna Announces End to Drug Rebates for Many Health Plans Beginning in 2027

3 months ago talkbio0Tagged brand-name prescriptions, Cigna, drug price, drug rebates, Evernorth, Express Scripts, manager, Pharmaceutical Services, pharmacy reimbursement, Trump administration, upfront discounts

Cigna; drug rebates; pharmacy benefit manager; Evernorth; Express Scripts; upfront discounts; brand-name prescriptions; pharmacy reimbursement; Trump administration; drug pricing

Expert Insights to Navigate Your CGT Challenges: Recent Updates and Strategic Guidance for 2025

3 months ago talkbio0Tagged calcium glucarate, Capital, Challenge, Changing, Cognitive function: planning, gains, Investments, Long-term, minimization, Private Equity, rates, Taxes

capital gains tax; CGT challenges; 2025 tax rates; long-term capital gains; tax planning; tax minimization strategies; Net Investment Income Tax; private equity tax changes

Intellia Pauses Two CRISPR Trials After Severe Liver Toxicity Hospitalizes Patient

3 months ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Hospitalization, Intellia, Liver, Pauses, Phase 3 Clinical Trials, Safety, Senile cardiac amyloidosis, Toxicity aspects

Intellia Therapeutics; CRISPR; transthyretin amyloidosis; Phase III trials; gene editing; liver toxicity; patient hospitalization; safety pause

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

3 months ago talkbio0Tagged Benefit, dealmaking, direct-to-consumer sales, drug price, gene therapy, Government, Hemlibra, Investments, manager, Manufacturing, Ocrevus, Pharmaceutical Services, pipeline, R&D, Roche (company), U.S., Vabysmo

Roche; drug pricing; US government; pharmacy benefit managers; direct-to-consumer sales; pipeline; dealmaking; US investment; manufacturing; gene therapy; R&D; Ocrevus; Hemlibra; Vabysmo

Epiminder Appoints Mark McLellan as Chief Financial Officer

3 months ago talkbio0Tagged Appointments, authorization, CFO, Epilepsy, Epiminder, healthcare finance, Mark McLellan, medical device company, Minder system, Preventive monitoring, United States Food and Drug Administration

Epiminder; Mark McLellan; CFO appointment; epilepsy monitoring; Minder system; FDA authorization; healthcare finance; medical device company

Somatix Readies Market Launch of First-of-its-Kind Wearable Medication Compliance Feature

3 months ago talkbio0Tagged Adherence To Medication Regime, AI-enabled, Detection, digital health, Gestures, partnering with, Presenile dementia, Preventive monitoring, Remote, Roche (company), SafeBeing platform, Somatix, Wearable Electronic Devices

Somatix; wearable technology; medication compliance; AI-enabled; gesture detection; remote patient monitoring; SafeBeing platform; dementia; partnering with Roche; digital health

Patient with Preexisting Immunity to AAV Vectors Granted Gene Therapy After Antibody-Depleting Agent Allowed Eligibility

4 months ago talkbio0Tagged AAV antibodies, antibody-chopping drug, Clinical Trials, Eligibility Determination, gene therapy

gene therapy; AAV antibodies; ineligible; antibody-chopping drug; clinical trial; eligibility

UK Proposes Raising Payment Scheme for Branded Medicines to Nearly 25% Amid Industry Pushback

4 months ago talkbio0Tagged Consultation, drugmakers, Industry, Nance-Horan syndrome, payment, pharmaceutical rebates, Pricing, Response process, spending, statutory scheme, UK

UK medicine pricing; NHS spending; statutory scheme; drugmakers; payment percentage; pharmaceutical rebates; industry response; consultation 2025

AI is Transforming Drug Safety—But Governance Sets Essential Guardrails

4 months ago talkbio0Tagged Adverse reaction to drug, AI guardrails, Artificial Intelligence, Bias (Epidemiology), Data Integrity, drug safety, Jeavons syndrome, patient safety, Pharmacovigilance, regulatory governance, United States Food and Drug Administration

artificial intelligence; drug safety; pharmacovigilance; adverse drug events; regulatory governance; FDA; EMEA; AI guardrails; data integrity; bias; patient safety

Legal Pressure Escalates as FDA Intensifies Crackdown on Direct-to-Consumer Pharma Advertising

4 months ago talkbio0Tagged Advertising (activity), CHARGE Syndrome, Compound, Direct-to-Consumer Advertising, enforcement, Legal Challenges, pharmaceutical advertising crackdown, Pharmacy facility, prescription drug ads, Preventive monitoring, United States Food and Drug Administration, warning letters

FDA enforcement; direct-to-consumer advertising; pharmaceutical advertising crackdown; warning letters; legal challenges; AI monitoring; prescription drug ads; transparency in advertising; HHS; compounding pharmacies